Unione Europea - italiano - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatite, atopica - altri preparati dermatologici - trattamento di moderata a dermatite atopica severa in adulti che non rispondono adeguatamente alla o che sono intolleranti alle terapie convenzionali quali i corticosteroidi topici. trattamento della dermatite atopica da moderata a grave nei bambini (di età pari o superiore a 2 anni) che non hanno risposto adeguatamente alle terapie convenzionali come i corticosteroidi topici. manutenzione, trattamento di moderata a grave dermatite atopica per la prevenzione delle riacutizzazioni e il prolungamento di flare-gli intervalli liberi in pazienti che presentano un'alta frequenza di riacutizzazioni di malattia (i. che si verificano 4 o più volte all'anno) che hanno avuto una risposta iniziale ad un massimo di 6 settimane di trattamento con un unguento di tacrolimus due volte al giorno (lesioni deselezionate, quasi azzerate o lievemente colpite).

Unione Europea - italiano - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatite, atopica - altri preparati dermatologici - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. che si verificano quattro o più volte all'anno), che hanno avuto una prima risposta a un massimo di sei settimane, il trattamento di tacrolimus unguento due volte al giorno (lesioni cancellato, quasi cancellato o moderatamente influenzato).

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatite, atopica - altri preparati dermatologici - staquis è indicato per il trattamento di entità da lieve a moderata dermatite atopica negli adulti e nei pazienti pediatrici dai 2 anni di età ≤ 40% di area di superficie corporea (bsa) interessati.

Unione Europea - italiano - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatite, atopica - altri preparati dermatologici - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti per dermatiti, esclusi i corticosteroidi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant può essere usato in monoterapia o in combinazione con metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopica - altri preparati dermatologici - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

zoetis belgium sa - lokivetmab - altri dermatologici preparazioni, agenti per le dermatiti, esclusi i corticosteroidi - cani - trattamento delle manifestazioni cliniche della dermatite atopica nei cani.

Italia - italiano - Ministero della Salute

uriage laboratoires dermatolog -